Sandeep Kumar Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandeep Kumar Gupta has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jayantee Kalita
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India
4 shared publications Dhiraj Kumar
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
2 shared publications- Dhiraj Kumar
Department of Neurology, Baba Raghav Das Medical College, Gorakhpur 273013, Uttar Pradesh, India
2 shared publications - Prakash C. Pandey
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India
2 shared publications - Roopali Mahajan
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India
2 shared publications Vivek Singh
Department of Radiodiagnosis, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1260
Temporal Kinetics of Circulating Oxidative Stress Markers in Intracerebral Hemorrhage and Their Association with Perihematoma Edema
In intracerebral hemorrhage (ICH), an elevated oxidant level may lead to perihematoma edema (PHE) and adversely affect its outcome. We report circulating oxidative stress markers in ICH patients at different time points and their association with PHE on computerized tomographic (CT) scans. A total of 87 patients with CT confirmed ICH within 24 h of ictus were prospectively included, and a follow-up CT scan was performed on day 7. The location and volume of hematoma, hematoma edema complex (HEC), PHE, and intraventricular extension of hemorrhage were noted on both CT scans. Blood samples were collected on days 1, 7, and 15, and reactive oxygen species (ROS), malondialdehyde (MDA), catalase (CAT), and glutathione peroxidase (GPx) levels were measured using a microplate reader. These biomarkers were also measured in 57 age-matched healthy controls. The patients had elevated ROS (p < 0.001) and MDA (p < 0.001) levels, whereas CAT (p < 0.001) and GPx (p < 0.001) levels were reduced compared to the controls. The oxidants remained elevated on day 7 and decreased on day 15 but did not reach the control levels. Furthermore, the CAT and GPx showed recovery on day 7 and day 15 but did not achieve the control levels. ROS (r = 0.28, p = 0.02) and GPx (r = −0.29, p = 0.02) correlated with PHE, suggesting their role in the pathogenesis. The hematoma volume, HEC, and PHE at day 1 correlated with the day 15 CAT level and MDA with PHE. At one month, 15 (17.24%) patients died, 56 (64.36%) had poor recovery, and 16 (18.39%) had good recovery. The patients with higher antioxidant levels had better survival and good outcomes. Future studies may investigate the efficacy of antioxidant therapy in improving clinical outcomes and modulating oxidative stress biomarkers in ICH patients.
- 1 October 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1260
Open AccessTemporal Kinetics of Circulating Oxidative Stress Markers in Intracerebral Hemorrhage and Their Association with Perihematoma Edema
In intracerebral hemorrhage (ICH), an elevated oxidant level may lead to perihematoma edema (PHE) and adversely affect its outcome. We report circulating oxidative stress markers in ICH patients at different time points and their association with PHE on computerized tomographic (CT) scans. A total of 87 patients with CT confirmed ICH within 24 h of ictus were prospectively included, and a follow-up CT scan was performed on day 7. The location and volume of hematoma, hematoma edema complex (HEC), PHE, and intraventricular extension of hemorrhage were noted on both CT scans. Blood samples were collected on days 1, 7, and 15, and reactive oxygen species (ROS), malondialdehyde (MDA), catalase (CAT), and glutathione peroxidase (GPx) levels were measured using a microplate reader. These biomarkers were also measured in 57 age-matched healthy controls. The patients had elevated ROS (p < 0.001) and MDA (p < 0.001) levels, whereas CAT (p < 0.001) and GPx (p < 0.001) levels were reduced compared to the controls. The oxidants remained elevated on day 7 and decreased on day 15 but did not reach the control levels. Furthermore, the CAT and GPx showed recovery on day 7 and day 15 but did not achieve the control levels. ROS (r = 0.28, p = 0.02) and GPx (r = −0.29, p = 0.02) correlated with PHE, suggesting their role in the pathogenesis. The hematoma volume, HEC, and PHE at day 1 correlated with the day 15 CAT level and MDA with PHE. At one month, 15 (17.24%) patients died, 56 (64.36%) had poor recovery, and 16 (18.39%) had good recovery. The patients with higher antioxidant levels had better survival and good outcomes. Future studies may investigate the efficacy of antioxidant therapy in improving clinical outcomes and modulating oxidative stress biomarkers in ICH patients.
- 12 May 2026
- Published by Elsevier in Epilepsy Research
- Vol. 225, 107822
mRNA profiling of caspase-3 and neurofilament light chain in Lennox-Gastaut Syndrome
- 12 May 2026
- Published by Elsevier in Epilepsy Research
- Vol. 225, 107822
mRNA profiling of caspase-3 and neurofilament light chain in Lennox-Gastaut Syndrome
- Open Access
- 2 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 352
Is Dexamethasone Helpful in Reducing Perihematoma Edema and for the Outcome of Intracerebral Hemorrhage?
Background: In primary supratentorial intracerebral hemorrhage (PSICH), dexamethasone (Dexa) may be effective in reducing perihematoma edema (PHE). We compare the changes in the PHE, hematoma edema complex (HEC), and midline shift (MLS) in patients with PSICH in the Dexa and Non-Dexa groups. Methods: The CT-proven PSICHs were included, and their stroke risk factors, Glasgow Coma Scale (GCS) score, and National Institute of Health Stroke Scale (NIHSS) score were noted. Thirty-one patients received intravenous dexamethasone from day 4 to day 7 of stroke in a dose of 24 mg, 12 mg, and 8 mg daily for 3 days each. Thirty-three patients did not receive dexamethasone. The primary outcome was the change in PHE, HEC, and MLS at 15 days compared to the pre-Dexa CT scan, and the secondary outcomes were death and disability at 3 months and side effects. Results: The Dexa group had a higher volume of ICH, HEC, and PHE, and MLS compared to the Non-Dexa group, although their age, NIHSS and GCS scores were comparable at admission and just before intervention. The Dexa group had a larger reduction in HEC (p = 0.03) and MLS (p < 0.01) compared to the Non-Dexa group. The change in PHE volume was also insignificantly higher in the Dexa group (p = 0.36). At 3 months, the patients with medium (p < 0.001) and large-size hematomas (p < 0.001) in the Dexa group had a good outcome, but this benefit was not observed in small hematomas. Conclusions: In PSICH, dexamethasone after 3 days reduces the HEC and MLS and may have survival and disability benefits especially in medium and large hematomas. A multicentric–randomized–controlled trial may confirm these findings.
- 2 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 352
Open AccessIs Dexamethasone Helpful in Reducing Perihematoma Edema and for the Outcome of Intracerebral Hemorrhage?
Background: In primary supratentorial intracerebral hemorrhage (PSICH), dexamethasone (Dexa) may be effective in reducing perihematoma edema (PHE). We compare the changes in the PHE, hematoma edema complex (HEC), and midline shift (MLS) in patients with PSICH in the Dexa and Non-Dexa groups. Methods: The CT-proven PSICHs were included, and their stroke risk factors, Glasgow Coma Scale (GCS) score, and National Institute of Health Stroke Scale (NIHSS) score were noted. Thirty-one patients received intravenous dexamethasone from day 4 to day 7 of stroke in a dose of 24 mg, 12 mg, and 8 mg daily for 3 days each. Thirty-three patients did not receive dexamethasone. The primary outcome was the change in PHE, HEC, and MLS at 15 days compared to the pre-Dexa CT scan, and the secondary outcomes were death and disability at 3 months and side effects. Results: The Dexa group had a higher volume of ICH, HEC, and PHE, and MLS compared to the Non-Dexa group, although their age, NIHSS and GCS scores were comparable at admission and just before intervention. The Dexa group had a larger reduction in HEC (p = 0.03) and MLS (p < 0.01) compared to the Non-Dexa group. The change in PHE volume was also insignificantly higher in the Dexa group (p = 0.36). At 3 months, the patients with medium (p < 0.001) and large-size hematomas (p < 0.001) in the Dexa group had a good outcome, but this benefit was not observed in small hematomas. Conclusions: In PSICH, dexamethasone after 3 days reduces the HEC and MLS and may have survival and disability benefits especially in medium and large hematomas. A multicentric–randomized–controlled trial may confirm these findings.
- 5 August 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 763-774
Association Between Hematoma Edema Complex and Outcomes of Primary Intracerebral Hemorrhage
Background Intracerebral hematoma (ICH) expansion occurs within 24 h, but perihematoma edema (PHE) may increase later due to blood breakdown products, leading to clinical deterioration and poor outcomes. There is a paucity of prospective studies evaluating the role of hematoma edema complex (HEC) and PHE in the death and disability of patients with ICH. We report the association between day 1 and day 7 HEC and PHE and outcomes at 3 months in patients with ICH. Methods Patients with primary ICH admitted within 24 h of ictus were included. Their demographic details, stroke risk factors, and Glasgow Coma Scale and National Institutes of Health Stroke Scale scores were recorded. A cranial computerized tomographic (CT) scan was done at admission and on the 7th day or earlier if there was clinical deterioration. Volumes of ICH, HEC, PHE, relative PHE, and midline shift were measured. Outcomes at 3 months were measured using the modified Rankin Scale. Results Ninety patients with a median age of 57 (range 38–80) years were included. The majority had ganglionic or thalamic ICH (70 patients, 77.8%), and 20 patients (22.2%) had lobar ICH. HEC, PHE, and midline shift significantly increased on the repeat CT scan. Baseline ICH volume correlated with expansion in HEC (r = 0.97, P < 0.0001) and PHE (r = 0.54, P < 0.001). There was an independent association between HEC on the repeat CT scan and death (adjusted odds ratio 1.05, 95% confidence interval 1.02–1.08, P < 0.001) and poor outcome (adjusted odds ratio 0.87; 95% confidence interval 0.78–0.98, P = 0.02). Conclusions There was an independent association between HEC and outcomes in patients with primary ICH.
- 5 August 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 763-774
Association Between Hematoma Edema Complex and Outcomes of Primary Intracerebral Hemorrhage
Background Intracerebral hematoma (ICH) expansion occurs within 24 h, but perihematoma edema (PHE) may increase later due to blood breakdown products, leading to clinical deterioration and poor outcomes. There is a paucity of prospective studies evaluating the role of hematoma edema complex (HEC) and PHE in the death and disability of patients with ICH. We report the association between day 1 and day 7 HEC and PHE and outcomes at 3 months in patients with ICH. Methods Patients with primary ICH admitted within 24 h of ictus were included. Their demographic details, stroke risk factors, and Glasgow Coma Scale and National Institutes of Health Stroke Scale scores were recorded. A cranial computerized tomographic (CT) scan was done at admission and on the 7th day or earlier if there was clinical deterioration. Volumes of ICH, HEC, PHE, relative PHE, and midline shift were measured. Outcomes at 3 months were measured using the modified Rankin Scale. Results Ninety patients with a median age of 57 (range 38–80) years were included. The majority had ganglionic or thalamic ICH (70 patients, 77.8%), and 20 patients (22.2%) had lobar ICH. HEC, PHE, and midline shift significantly increased on the repeat CT scan. Baseline ICH volume correlated with expansion in HEC (r = 0.97, P < 0.0001) and PHE (r = 0.54, P < 0.001). There was an independent association between HEC on the repeat CT scan and death (adjusted odds ratio 1.05, 95% confidence interval 1.02–1.08, P < 0.001) and poor outcome (adjusted odds ratio 0.87; 95% confidence interval 0.78–0.98, P = 0.02). Conclusions There was an independent association between HEC and outcomes in patients with primary ICH.
- Open Access
- 4 April 2025
- Published by Heighten Science Publications Corporation in Journal of Neuroscience and Neurological Disorders
- Vol. 9 (1) , 039-045
A Comparative Study of Metoprolol and Amlodipine on Mortality, Disability and Complication in Acute Stroke
Stress in acute stroke may increase mortality and complications, but there is a paucity of information on the efficacy of beta blockers over other anti-hypertensive. To report efficacy of metoprolol over amlodipine in reducing mortality, disability and infections in acute stroke. CT/MRI confirmed stroke patients within 3 days of onset were included whose age was 18 to 75 years. Patients with secondary intracerebral hemorrhage, organ failure, pregnancy, malignancy, and immunosuppressant or on beta-blocker/amlodipine were excluded. Stroke risk factors, Glasgow Coma Scale (GCS) score, National Institute of Health Stroke Scale (NIHSS) score and CT/MRI findings were noted. Patients with a blood pressure of > 160/90 mm of Hg were randomized using 1:1 randomization to metoprolol (25 mg on day 1, 50 mg if BP is not controlled) or amlodipine (2.5 mg on day 1, then 5 mg then 10 mg on, subsequent days if BP is not controlled). Other standard treatment was continued. The primary outcome was mortality at 1 month; secondary outcomes included were in-hospital gastrointestinal hemorrhage, pneumonia, sepsis and 3 months functional outcome based on modified Rankin Scale (mRS). Side effects were noted. 18 (14.4%) patients died; 6 (9.7%) in metoprolol and 12 (19%) in amlodipine (p = 0.20) group. At 3-months, 66 patients had good outcome; 45 (80.4%) in metoprolol and 21 (43.3%) in amlodipine group (p < 0.001). The other secondary outcomes were comparable between the two groups. Metoprolol was withdrawn in 6 patients due to bradycardia, and amlodipine in 5 due to hypotension and in 1 due to allergic reaction. Metoprolol is associated with improved functional outcomes in acute stroke compared to amlodipine.
- 4 April 2025
- Published by Heighten Science Publications Corporation in Journal of Neuroscience and Neurological Disorders
- Vol. 9 (1) , 039-045
Open AccessA Comparative Study of Metoprolol and Amlodipine on Mortality, Disability and Complication in Acute Stroke
Stress in acute stroke may increase mortality and complications, but there is a paucity of information on the efficacy of beta blockers over other anti-hypertensive. To report efficacy of metoprolol over amlodipine in reducing mortality, disability and infections in acute stroke. CT/MRI confirmed stroke patients within 3 days of onset were included whose age was 18 to 75 years. Patients with secondary intracerebral hemorrhage, organ failure, pregnancy, malignancy, and immunosuppressant or on beta-blocker/amlodipine were excluded. Stroke risk factors, Glasgow Coma Scale (GCS) score, National Institute of Health Stroke Scale (NIHSS) score and CT/MRI findings were noted. Patients with a blood pressure of > 160/90 mm of Hg were randomized using 1:1 randomization to metoprolol (25 mg on day 1, 50 mg if BP is not controlled) or amlodipine (2.5 mg on day 1, then 5 mg then 10 mg on, subsequent days if BP is not controlled). Other standard treatment was continued. The primary outcome was mortality at 1 month; secondary outcomes included were in-hospital gastrointestinal hemorrhage, pneumonia, sepsis and 3 months functional outcome based on modified Rankin Scale (mRS). Side effects were noted. 18 (14.4%) patients died; 6 (9.7%) in metoprolol and 12 (19%) in amlodipine (p = 0.20) group. At 3-months, 66 patients had good outcome; 45 (80.4%) in metoprolol and 21 (43.3%) in amlodipine group (p < 0.001). The other secondary outcomes were comparable between the two groups. Metoprolol was withdrawn in 6 patients due to bradycardia, and amlodipine in 5 due to hypotension and in 1 due to allergic reaction. Metoprolol is associated with improved functional outcomes in acute stroke compared to amlodipine.